In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin

Fosmidomycin acts through inhibition of 1-deoxy-d-xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme of the nonmevalonate pathway of isoprenoid biosynthesis. It possesses potent antimalarial activity in vitro and in murine malaria. In a recent clinical study, fosmidomycin was effective and w...

Cijeli opis

Bibliografski detalji

Izdano u:	Antimicrob Agents Chemother
Glavni autori:	Wiesner, Jochen, Henschker, Dajana, Hutchinson, David B., Beck, Ewald, Jomaa, Hassan
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology (ASM) 2002
Teme:	Experimental Therapeutics
Online pristup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC127394/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12183243/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.46.9.2889-2894.2002
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!